Lataa...
Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure based drug design
[Image: see text] CXCL12 is an attractive target for clinical therapy because of its involvement in autoimmune diseases, cancer growth, metastasis, and neovascularization. Tyrosine sulfation at three positions in the CXCR4 N-terminus is crucial for specific, high-affinity CXCL12 binding. An NMR stru...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2941798/ https://ncbi.nlm.nih.gov/pubmed/20459090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ja1002263 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|